PVX2 / PapiVax - LARVOL DELTA

Fe3O4 Nanozyme-Labeled Lateral Flow Immunochromatography Strips for Rapid Detection of PVX and PVY. (PubMed, Plants (Basel)) - "Western blot analysis demonstrated that four monoclonal antibodies (PVX 2, PVX 6, PVY 2, and PVY 5) specifically recognized their corresponding viral coat proteins...In addition, detection results by strips from 12 samples of plantlets in vitro were fully consistent with RT-PCR. These nanozyme strips provide rapid, simple, specific, and sensitive methods that can be stored at ambient temperature, enabling field surveys, warehouse screening, and on-site testing and supporting early detection of potato virus diseases."

Journal • Infectious Disease

Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer (clinicaltrials.gov) - P1 | N=14 | Completed | Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Active, not recruiting ➔ Completed

Trial completion • Cervical Cancer • Oncology • Solid Tumor

Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer (clinicaltrials.gov) - P1 | N=14 | Active, not recruiting | Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial primary completion date: Mar 2024 ➔ Dec 2024

Trial primary completion date • Cervical Cancer • Oncology • Solid Tumor

PVX-2: Phase II Study of Treatment for HPV16+ ASC-US, ASC-H and LSIL (clinicaltrials.gov) - P2 | N=16 | Terminated | Sponsor: PapiVax Biotech, Inc. | N=134 ➔ 16 | Recruiting ➔ Terminated; Slow recruitment/funding

Cytology • Enrollment change • Trial termination

Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer (clinicaltrials.gov) - P1 | N=14 | Active, not recruiting | Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Jan 2024 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Mar 2024

Trial completion date • Trial primary completion date • Cervical Cancer • Oncology • Solid Tumor • CD4

SAFETY RUN-IN OF INTRAMUSCULAR PNGVL4A-SIG/E7(DETOX)/HSP70 DNA AND TA-CIN PROTEIN VACCINATION AS TREATMENT FOR HPV16+ ASC-US, ASC-H, OR LSIL/CIN1 (IPVC 2023) - P2 | "At month 6, 45% (5/11) of participants converted to HPV16-negative and 2 others developed CIN2+ and received a LEEP. At month 12, 64% (7/11) were HPV16-negative, including those HPV16-negative at month 6.Conclusions The PVX2 immunotherapy was well tolerated and associated with viral regression, supporting further testing."

Clinical • Gynecology • Infectious Disease